drugset / Trial / NCT06531122

Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis

NCT06531122

Phase 3 Recruiting 200 enrolled Kafrelsheikh University
RandomizedParallel-groupDouble-blindTreatment

Summary

Along with the current clinical trial, the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral heamoragic complications.

Timeline

Start
2021-08-01
Primary completion
2024-09-01
Completion
2024-09-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apixaban Small molecule 5 mg
Comparator Rivaroxaban Other / unclassified 20 mg Oral